Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal KESANS : International Journal of Health and Science
Avifa, Serly
Unknown Affiliation
Chemistry Health Professions Medicine & Pharmacology Physics Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Analysis of the Risk of Kidney Dysfunction due to Heparin vs Clopidogrel Therapy in Vascular Thrombosis Patients: A Retrospective Study Maulana Kamri, Andi; Sukmawati, Sukmawati; Avifa, Serly
Jurnal KESANS : Kesehatan dan Sains Vol 4 No 11 (2025): KESANS: International Journal of Health and Science
Publisher : Rifa'Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.54543/kesans.v4i11.390

Abstract

Introduction: The repeated use of anticoagulants like heparin and antiplatelets such as clopidogrel in individuals with vascular thrombosis necessitates an evaluation of the nephrotoxicity risk. Objective: This study seeks to assess the impacts of heparin and clopidogrel on renal function. Method: This cohort retrospective design examined data from 120 individuals with vascular thrombosis who were administered heparin (n=60) or clopidogrel (n=60). Renal parameters (serum creatinine, eGFR) were evaluated prior to and following therapy. The statistical analysis employed a paired t-test and multivariate logistic regression, utilising a 95% confidence interval. Results and Discussion: The heparin cohort had a notable elevation in serum creatinine (1.8±0.4 vs 1.2±0.3 mg/dL; p=0.02) and a reduction in eGFR (45±12 vs 68±15 mL/min/1.73m²; p=0.01) in comparison to the clopidogrel group. Therapy exceeding 7 days elevated the incidence of renal impairment by 2.3-fold (OR: 2.3; 95% CI: 1.4-3.8) in the heparin cohort. The nephrotoxic impact of heparin is much greater in patients with cardiovascular comorbidities (p=0.04). Conclusion: Heparin presents a greater risk of inducing renal dysfunction than clopidogrel, particularly with prolonged usage and in individuals with concomitant conditions. Rigorous oversight of renal function and evaluation of alternate treatments are advised.
Co-Authors Andi Maulana Kamri Sukmawati Sukmawati